WallStreetZenWallStreetZen

NASDAQ: GYRE
Gyre Therapeutics Inc Stock

$17.53+0.74 (+4.41%)
Updated Mar 27, 2024
GYRE Price
$17.53
Fair Value Price
N/A
Market Cap
$1.50B
52 Week Low
$2.85
52 Week High
$30.40
P/E
-12.43x
P/B
-94.61x
P/S
14.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$113.45M
Earnings
-$92.93M
Gross Margin
95.9%
Operating Margin
-74.41%
Profit Margin
-81.9%
Debt to Equity
-2.41
Operating Cash Flow
$26M
Beta
1.15
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GYRE Overview

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GYRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GYRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GYRE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
GYRE's Earnings (EBIT) of -$84.42M... subscribe to Premium to read more.
Interest Coverage Financials
There are 35 more GYRE due diligence checks available for Premium users.

Be the first to know about important GYRE news, forecast changes, insider trades & much more!

GYRE News

Valuation

GYRE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-12.43x
Industry
14.3x
Market
44.45x

GYRE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-94.61x
Industry
6.2x

GYRE's financial health

Profit margin

Revenue
$113.5M
Net Income
-$89.1M
Profit Margin
-78.6%
GYRE's Earnings (EBIT) of -$84.42M... subscribe to Premium to read more.
Interest Coverage Financials
GYRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$116.5M
Liabilities
$38.1M
Debt to equity
-2.41
GYRE's short-term assets ($57.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GYRE's short-term assets ($57.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GYRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$37.8M
Investing
-$25.0M
Financing
$15.2M
GYRE's operating cash flow ($25.89M)... subscribe to Premium to read more.
Debt Coverage Financials

GYRE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GYRE$1.50B+4.41%-12.43x-94.61x
IRON$1.49B+0.35%-17.69x4.33x
ADMA$1.54B+3.69%-51.85x11.38x
KNSA$1.41B+0.10%99.95x3.22x
SLNO$1.39B-0.81%-18.16x8.83x

Gyre Therapeutics Stock FAQ

What is Gyre Therapeutics's quote symbol?

(NASDAQ: GYRE) Gyre Therapeutics trades on the NASDAQ under the ticker symbol GYRE. Gyre Therapeutics stock quotes can also be displayed as NASDAQ: GYRE.

If you're new to stock investing, here's how to buy Gyre Therapeutics stock.

What is the 52 week high and low for Gyre Therapeutics (NASDAQ: GYRE)?

(NASDAQ: GYRE) Gyre Therapeutics's 52-week high was $30.40, and its 52-week low was $2.85. It is currently -42.34% from its 52-week high and 515.09% from its 52-week low.

How much is Gyre Therapeutics stock worth today?

(NASDAQ: GYRE) Gyre Therapeutics currently has 85,423,246 outstanding shares. With Gyre Therapeutics stock trading at $17.53 per share, the total value of Gyre Therapeutics stock (market capitalization) is $1.50B.

Gyre Therapeutics stock was originally listed at a price of $13,639.50 in Apr 12, 2006. If you had invested in Gyre Therapeutics stock at $13,639.50, your return over the last 17 years would have been -99.87%, for an annualized return of -32.4% (not including any dividends or dividend reinvestments).

How much is Gyre Therapeutics's stock price per share?

(NASDAQ: GYRE) Gyre Therapeutics stock price per share is $17.53 today (as of Mar 27, 2024).

What is Gyre Therapeutics's Market Cap?

(NASDAQ: GYRE) Gyre Therapeutics's market cap is $1.50B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gyre Therapeutics's market cap is calculated by multiplying GYRE's current stock price of $17.53 by GYRE's total outstanding shares of 85,423,246.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.